Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHWE7P)

• Drug Name: Ampicillin Drug Info
• Synonyms: ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Acute epiglottitis		Approved	[1]
Acute gonococcal cervicitis		Approved	[1]
Acute otitis media	AB00	Approved	[1]
Bacillary dysentery	1A02	Approved	[1]
Bacteremia	1A73	Approved	[1]
Bacterial endocarditis		Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Cholangitis		Approved	[1]
Chorioamnionitis		Approved	[1]
Dysentery		Approved	[1]
Escherichia coli meningitis		Approved	[1]
Meningococcal meningitis		Approved	[1]
Peritonitis		Approved	[1]
Pneumococcal meningitis		Approved	[1]
Staphylococcal pneumonia		Approved	[1]
Staphylococcus aureus infection		Approved	[1]
Streptococcal pneumonia		Approved	[1]
Urinary tract infection	GC08	Approved	[1]
Paratyphoid fever		Investigative	[1]
Pelvic inflammatory disease	GA05	Investigative	[1]
Sinusitis	CA0A.Z	Investigative	[1]

• Therapeutic Class: Antibiotics
• Cross-matching ID:
  PubChem CID: 6249
  ChEBI ID: CHEMBL174
  CAS Number: CAS 69-53-4
  TTD Drug ID: DMHWE7P
  VARIDT Drug ID: DR00712
  INTEDE Drug ID: DR2177
  ACDINA Drug ID: D00037

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Penicillin binding protein (Bact PBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[15]
Ceftriaxone	DMCEW64	Acute gonococcal cervicitis		Approved	[16]
Ticarcillin	DM4ME02	Aspiration pneumonia		Approved	[17]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[18]
Meropenem	DM62UHC	Bacterial infection	1A00-1C4Z	Approved	[16]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[19]
Clofarabine	DMCVJ86	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[21]
Carbenicillin	DMLEDNK	Infection of the upper and lower urinary tract	GC08	Approved	[22]
Piperacillin	DMTBKF3	Acute gonococcal cervicitis		Approved	[23]

Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[24]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[25]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[26]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[27]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[28]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[30]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[31]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[32]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[33]

Drug(s) Transported By Peptide transporter 1 (SLC15A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[34]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[35]
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[36]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[37]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[38]
Ceftriaxone	DMCEW64	Acute gonococcal cervicitis		Approved	[39]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[35]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[36]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[36]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[36]

Drug(s) Transported By Peptide transporter 2 (SLC15A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[34]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[40]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[41]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[42]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[4]
Valaciclovir	DMHKS94	Genital herpes	1A94	Approved	[43]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[34]
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[44]
Spirapril	DM5XLTY	Hypertension	BA00-BA04	Approved	[45]
Cefixime	DMY60I8	Acute gonococcal cervicitis		Approved	[4]

Drug(s) Metabolized By N-acylhomoserine lactone acylase (lacA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[7]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[7]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[7]
Carbenicillin	DMLEDNK	Infection of the upper and lower urinary tract	GC08	Approved	[7]
Benzylpenicillin	DMS9503	Actinomycosis		Phase 3	[7]

Drug(s) Metabolized By Beta-lactamase (blaB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[46]
Piperacillin	DMTBKF3	Acute gonococcal cervicitis		Approved	[8]
Cefalotin	DMVYSLE	Bacteremia	1A73	Approved	[8]
Benzylpenicillin	DMS9503	Actinomycosis		Phase 3	[8]
Cephaloridine	DM4Y95F	Gram-positive bacterial infection	1B74-1G40	Withdrawn from market	[8]
Ceftiofur	DMR2SOZ	Bacterial infection	1A00-1C4Z	Approved	[47]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[48]
Benzylpenicillin	DMS9503	Actinomycosis		Phase 3	[49]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[48]
Carbenicillin	DMLEDNK	Infection of the upper and lower urinary tract	GC08	Approved	[12]
Imipenem	DMI9FBP	Bacteremia	1A73	Approved	[50]
Ceftriaxone	DMCEW64	Acute gonococcal cervicitis		Approved	[10]
Meropenem	DM62UHC	Bacterial infection	1A00-1C4Z	Approved	[50]
Carbapenem	DMXZU73	N. A.	N. A.	Phase 4	[51]
Ceftazidine	DMPZTRC	N. A.	N. A.	Phase 4	[10]

Drug(s) Metabolized By AmpC beta-lactamase (ampC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imipenem	DMI9FBP	Bacteremia	1A73	Approved	[11]
Cefalotin	DMVYSLE	Bacteremia	1A73	Approved	[11]

Drug(s) Affected By Phospholemman (FXYD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[54]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[57]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[58]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[59]

Drug(s) Affected By Interferon-related developmental regulator 1 (IFRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[60]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[63]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[65]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]

Drug(s) Affected By CCN family member 1 (CCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[70]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[69]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]

Drug(s) Affected By Calmegin (CLGN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[69]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[65]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[77]

Drug(s) Affected By ATP-binding cassette sub-family C member 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[78]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[79]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[80]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[81]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[82]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[84]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[85]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[86]

Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[88]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[89]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[90]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[91]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[66]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[93]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[94]

Drug(s) Affected By Chloride intracellular channel protein 3 (CLIC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[97]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[58]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[59]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[98]

Drug(s) Affected By Ceruloplasmin (CP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[100]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[104]

Drug(s) Affected By Metalloproteinase inhibitor 1 (TIMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[105]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[106]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[107]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[107]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[109]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[111]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[112]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[113]

Drug(s) Affected By Cystatin-A (CSTA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[83]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[115]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[116]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[63]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[117]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[118]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[82]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[119]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[120]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[119]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[121]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[119]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]

Drug(s) Affected By Creatine kinase B-type (CKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[123]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[124]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[124]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[125]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[126]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]

Drug(s) Affected By Transcription factor JunD (JUND)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[127]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[128]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[130]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[132]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[133]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[134]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[135]

Drug(s) Affected By Gastricsin (PGC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[65]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[137]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[138]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[139]

Drug(s) Affected By Parathymosin (PTMS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[141]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[143]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[114]

Drug(s) Affected By Protein-lysine 6-oxidase (LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[145]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[148]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[149]

Drug(s) Affected By Sodium- and chloride-dependent creatine transporter 1 (SLC6A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[150]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[104]

Drug(s) Affected By Rho GDP-dissociation inhibitor 1 (ARHGDIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[151]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[152]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[153]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[126]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[154]

Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[155]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[156]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[157]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[155]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[158]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[155]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[159]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[160]

Drug(s) Affected By Myc-associated zinc finger protein (MAZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[161]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Bortezomib	DMNO38U	Leukemia		Approved	[162]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[163]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[143]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[164]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[165]

Drug(s) Affected By Tropomyosin alpha-4 chain (TPM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[167]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]

Drug(s) Affected By 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[100]
Calcidiol	DMN4CV5	Hypophosphatemia		Approved	[168]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[169]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[170]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[171]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[172]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[173]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[137]

Drug(s) Affected By Ankyrin repeat domain-containing protein 1 (ANKRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[75]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[174]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[175]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[141]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]

Drug(s) Affected By Na(+)/H(+) exchange regulatory cofactor NHE-RF2 (NHERF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[121]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[177]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[178]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[178]

Drug(s) Affected By Carbonic anhydrase 9 (CA9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[179]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[145]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[180]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[181]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[141]
Bortezomib	DMNO38U	Leukemia		Approved	[182]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[183]

Drug(s) Affected By Dual specificity protein phosphatase 7 (DUSP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[137]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[137]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[184]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[185]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[138]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[186]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]

Drug(s) Affected By 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[187]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[132]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[130]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[188]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[132]

Drug(s) Affected By Filamin A-interacting protein 1-like (FILIP1L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[181]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[190]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[104]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[191]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]

Drug(s) Affected By Glycerol-3-phosphate acyltransferase 3 (GPAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[66]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[101]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[101]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[192]

Drug(s) Affected By Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[110]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[89]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[193]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]

Drug(s) Affected By Leukocyte-associated immunoglobulin-like receptor 2 (LAIR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[194]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[195]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[196]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[197]

Drug(s) Affected By Sterile alpha motif domain-containing protein 1 (SAMD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[194]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[59]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[198]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[161]

Drug(s) Affected By Lipocalin-15 (LCN15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[58]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[199]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[200]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[201]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[194]

Drug(s) Affected By Protein MTSS 2 (MTSS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[202]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[190]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[138]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[203]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[198]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[204]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[161]

Drug(s) Affected By Solute carrier family 22 member 15 (SLC22A15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[150]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[205]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[141]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[206]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[207]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]

Drug(s) Affected By BPI fold-containing family B member 2 (BPIFB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[190]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[200]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[201]
OXYQUINOLINE	DMZVS9Y	Discovery agent	N.A.	Investigative	[13]

Drug(s) Affected By Arrestin domain-containing protein 4 (ARRDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[174]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[208]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[104]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]

Drug(s) Affected By Phospholipid phosphatase-related protein type 1 (PLPPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[209]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[52]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[194]
OXYQUINOLINE	DMZVS9Y	Discovery agent	N.A.	Investigative	[13]

Drug(s) Affected By Jun dimerization protein 2 (JDP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[75]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[210]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[185]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[138]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[211]

Drug(s) Affected By Arrestin domain-containing protein 3 (ARRDC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[212]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[130]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[137]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[137]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]

Drug(s) Affected By Small integral membrane protein 14 (SMIM14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[213]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[137]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[213]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[213]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[210]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[141]
Bleomycin	DMNER5S	Cervical cancer	2C77.0	Approved	[213]

Drug(s) Affected By Sulfiredoxin-1 (SRXN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[82]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[146]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[91]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[214]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[63]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[101]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[101]

Drug(s) Affected By Homeobox protein Hox-D1 (HOXD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[196]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[188]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[207]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[215]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]

Drug(s) Affected By Regulator of cell cycle RGCC (RGCC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[89]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[205]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[216]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[53]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[217]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[218]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[206]

Drug(s) Affected By Serine/threonine-protein kinase Sgk2 (SGK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[89]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[64]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[219]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[209]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[89]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[87]

Drug(s) Affected By Endothelial cell-specific molecule 1 (ESM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[220]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[221]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[222]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[223]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[224]
PD-0325901	DM27D4J	Breast cancer	2C60-2C65	Phase 2	[225]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[226]

Drug(s) Affected By ]-phosphatase 2, mitochondrial (PDP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[206]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[185]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[59]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[52]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[204]

Drug(s) Affected By Cell cycle progression protein 1 (CCPG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[227]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[76]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Bortezomib	DMNO38U	Leukemia		Approved	[227]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[55]
Indomethacin	DMSC4A7	Bursitis		Approved	[228]

Drug(s) Affected By Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) (SLC6A14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[87]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[190]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[207]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[229]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[87]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[52]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[142]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[59]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[229]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[200]

Drug(s) Affected By Proliferation-associated protein 2G4 (PA2G4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[230]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[231]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[153]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[190]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[184]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[232]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[222]

Drug(s) Affected By Pirin (PIR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[61]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[124]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[134]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[202]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[101]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[101]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[190]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[233]

Drug(s) Affected By Tripartite motif-containing protein 16 (TRIM16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[234]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[74]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[235]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[103]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[104]
Penicillin V	DMKVOYF	Acute otitis media	AB00	Approved	[233]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[236]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[237]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[238]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[239]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[240]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[241]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[242]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[127]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[243]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[244]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[245]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[246]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[244]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 5 (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[247]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[248]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[140]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[249]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[126]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[250]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[248]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[147]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[194]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[251]

Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[252]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[254]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[255]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[133]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[256]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[257]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Penicillin binding protein (Bact PBP)	TTJP4SM	NOUNIPROTAC	Binder	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[4]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[5]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
N-acylhomoserine lactone acylase (lacA)	DEIU0XN	A0A0A1VBK6_9BURK	Substrate	[7]
Beta-lactamase (blaB)	DET9I1W	BLAC_BACUN	Substrate	[8]
Beta-lactamase (blaB)	DETDS7E	A0A2S0LB67_9FLAO	Substrate	[9]
Beta-lactamase (blaB)	DEC7JEF	A0A1S1G219_9NEIS	Substrate	[9]
Beta-lactamase (blaB)	DEBKS91	A0A1B1FBM9_ACIBA	Substrate	[10]
AmpC beta-lactamase (ampC)	DERI7LO	A0A0H3KQ39_BURM1	Substrate	[11]
Beta-lactamase (blaB)	DEWYT5M	D4HFC4_CUTAS	Substrate	[9]
Beta-lactamase (blaB)	DE3FVRW	BLA2_BAC17	Substrate	[9]
Beta-lactamase (blaB)	DEG5Y4W	A0A344X3A2_STASP	Substrate	[9]
Beta-lactamase (blaB)	DEQX0DG	Q8RIK5_FUSNN	Substrate	[9]
Beta-lactamase (blaB)	DEXB2A9	A0A379CPC3_PLESH	Substrate	[12]
Beta-lactamase (blaB)	DEWMGC3	A0A2U9SV73_9BURK	Substrate	[9]
Beta-lactamase (blaB)	DE52KD0	Q6EZ46_RALPI	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[13]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)	OT25JBA3	F263_HUMAN	Gene/Protein Processing	[13]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Gene/Protein Processing	[13]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[13]
Ankyrin repeat domain-containing protein 1 (ANKRD1)	OTHJ7JV9	ANKR1_HUMAN	Gene/Protein Processing	[13]
Arrestin domain-containing protein 3 (ARRDC3)	OTAKW7R9	ARRD3_HUMAN	Gene/Protein Processing	[13]
Arrestin domain-containing protein 4 (ARRDC4)	OTINJ0FX	ARRD4_HUMAN	Gene/Protein Processing	[13]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Gene/Protein Processing	[13]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Regulation of Drug Effects	[14]
BPI fold-containing family B member 2 (BPIFB2)	OTXWTWQ9	BPIB2_HUMAN	Gene/Protein Processing	[13]

References

• [1] Ampicillin FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936.
• [3] Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
• [4] Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
• [5] Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
• [6] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [7] A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
• [8] Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
• [9] Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
• [10] Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
• [11] Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
• [12] Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
• [13] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [14] Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
• [15] Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
• [18] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [19] Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
• [20] Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
• [21] Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
• [22] Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
• [23] In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6.
• [24] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [25] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [26] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [27] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [28] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [29] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [30] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [31] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [32] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [33] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [34] Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
• [35] Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
• [36] High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
• [37] The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
• [38] Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
• [39] Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
• [40] Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
• [41] The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
• [42] Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
• [43] Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
• [44] PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
• [45] Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
• [46] Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
• [47] The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
• [48] Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
• [49] beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. Antimicrob Agents Chemother. 1999 May;43(5):1270-3.
• [50] A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
• [51] Investigation of carbapenemases and aminoglycoside modifying enzymes of Acinetobacter baumannii isolates recovered from patients admitted to intensive care units in a tertiary-care hospital in Brazil. Rev Soc Bras Med Trop. 2019 Dec 20;53:e20190044.
• [52] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [53] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [54] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [55] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [56] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [57] Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data. Toxicol Sci. 2018 May 1;163(1):182-195. doi: 10.1093/toxsci/kfy012.
• [58] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [59] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [60] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [61] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [62] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [63] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [64] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [65] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [66] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [67] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [68] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [69] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [70] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [71] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [72] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [73] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [74] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [75] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [76] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [77] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [78] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [79] Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
• [80] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [81] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [82] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [83] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [84] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [85] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [86] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [87] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [88] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [89] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [90] Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
• [91] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [92] Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
• [93] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [94] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [95] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [96] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [97] Transforming growth factor beta1 targets estrogen receptor signaling in bronchial epithelial cells. Respir Res. 2018 Aug 30;19(1):160. doi: 10.1186/s12931-018-0861-5.
• [98] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [99] Reactive oxygen species regulate ceruloplasmin by a novel mRNA decay mechanism involving its 3'-untranslated region: implications in neurodegenerative diseases. J Biol Chem. 2009 Jan 16;284(3):1873-83. doi: 10.1074/jbc.M804079200. Epub 2008 Nov 18.
• [100] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [101] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [102] In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol. 2016 Mar;90(3):677-89. doi: 10.1007/s00204-015-1483-z. Epub 2015 Feb 26.
• [103] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [104] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [105] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [106] Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012 Apr;26(4):1535-48. doi: 10.1096/fj.11-198184. Epub 2011 Dec 23.
• [107] Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
• [108] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [109] Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res. 2001 Sep 1;480-481:269-76. doi: 10.1016/s0027-5107(01)00184-1.
• [110] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [111] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [112] Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
• [113] Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
• [114] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [115] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [116] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [117] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [118] Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
• [119] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [120] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [121] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [122] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [123] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [124] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [125] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [126] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [127] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [128] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [129] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [130] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [131] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [132] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [133] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [134] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [135] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [136] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [137] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [138] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [139] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [140] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [141] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [142] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [143] Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells. Mol Carcinog. 2006 Oct;45(10):752-63.
• [144] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [145] NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
• [146] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [147] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [148] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [149] Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
• [150] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [151] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [152] Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
• [153] [Differential proteomic expression in human liver cells stimulated by hydroquinone]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 Nov;24(11):658-61.
• [154] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [155] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [156] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [157] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [158] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [159] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [160] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [161] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [162] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [163] Gene alterations of ovarian cancer cells expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. Lab Anim Res. 2011 Jun;27(2):99-107. doi: 10.5625/lar.2011.27.2.99. Epub 2011 Jun 22.
• [164] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [165] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [166] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [167] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [168] Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973-81. doi: 10.1016/j.bbrc.2005.10.178. Epub 2005 Nov 7.
• [169] Actions of Vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20-6.
• [170] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [171] Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86.
• [172] 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005 Mar 15;65(6):2488-97.
• [173] Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
• [174] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [175] High folic acid increases cell turnover and lowers differentiation and iron content in human HT29 colon cancer cells. Br J Nutr. 2008 Apr;99(4):703-8.
• [176] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [177] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [178] Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
• [179] Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem. 2011 Oct 13;54(19):6905-18.
• [180] Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochem Res. 2012 Feb;37(2):370-80. doi: 10.1007/s11064-011-0620-1. Epub 2011 Oct 4.
• [181] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [182] A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005 Aug 1;11(15):5526-33. doi: 10.1158/1078-0432.CCR-05-0081.
• [183] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [184] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [185] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [186] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [187] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [188] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [189] Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells. BMB Rep. 2010 Sep;43(9):599-603. doi: 10.5483/BMBRep.2010.43.9.599.
• [190] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [191] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [192] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [193] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [194] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [195] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [196] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [197] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [198] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [199] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
• [200] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [201] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [202] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [203] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [204] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [205] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [206] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [207] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [208] Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.
• [209] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [210] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [211] Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology. 2008 Oct;149(10):4809-20. doi: 10.1210/en.2008-0035. Epub 2008 Jun 12.
• [212] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [213] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [214] Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
• [215] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [216] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [217] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [218] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [219] Serum- and glucocorticoid-regulated kinase 2 determines drug-activated pregnane X receptor to induce gluconeogenesis in human liver cells. J Pharmacol Exp Ther. 2014 Jan;348(1):131-40. doi: 10.1124/jpet.113.209379. Epub 2013 Nov 7.
• [220] In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs. 2008 Nov;17(11):1623-33. doi: 10.1517/13543784.17.11.1623.
• [221] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [222] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [223] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [224] A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
• [225] PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014 Oct 9;514(7521):247-51.
• [226] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [227] Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
• [228] Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia. 2007 Mar;9(3):222-35.
• [229] Oestrogenic potencies of Zeranol, oestradiol, diethylstilboestrol, Bisphenol-A and genistein: implications for exposure assessment of potential endocrine disrupters. Hum Reprod. 2001 May;16(5):1037-45.
• [230] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [231] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [232] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [233] Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
• [234] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [235] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [236] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [237] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [238] Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis. 2008 Apr;29(4):779-89.
• [239] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [240] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [241] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [242] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [243] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [244] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [245] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [246] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [247] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [248] Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
• [249] Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
• [250] 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000 Mar 1;164(5):2405-11. doi: 10.4049/jimmunol.164.5.2405.
• [251] Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia. 2010 Aug;24(8):1476-86. doi: 10.1038/leu.2010.117. Epub 2010 Jun 3.
• [252] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [253] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [254] ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
• [255] Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
• [256] Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
• [257] Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.